Results 241 to 250 of about 3,285,539 (279)

Death receptors in chemotherapy and cancer [PDF]

Oncogene, 2004
Apoptosis, the cell's intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies such as chemotherapy, gamma-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target ...
Klaus-Michael Debatin
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors

Biochemical and Biophysical Research Communications, 2005
Death receptors (DRs) can induce apoptosis by oligomerization with TRAIL, whereas death decoy receptors (DcRs) cannot, due to their lack of functional intracellular death domains. However, it is not known whether DRs and DcRs can interact with one another to form oligomeric complexes prior to TRAIL binding.
Myung-Hee Kwon, Yong-Sung Kim
exaly   +3 more sources

Death receptors

Essays in Biochemistry, 2003
Death receptors [Fas/Apo-1/CD95, TNF-R1 [tumour necrosis factor (TNF) receptor 1], DR3 [death receptor 3], TRAIL-R1 [TNF-related apoptosis-inducing ligand receptor 1], TRAIL-R2, DR6, p75-NGFR [p75-nerve growth factor receptor], EDAR [ectodermal dysplasia receptor]] form a subgroup of the TNF-R superfamily that can induce apoptosis (programmed cell ...
openaire   +2 more sources

Death Receptor Ligands in Tumors

Journal of Immunotherapy, 2002
Activation of apoptosis via death receptors is a tightly regulated event, and the death pathway itself is open to interference on the part of soluble or membrane-bound decoy receptors. The aggregation state of the death-inducing ligand is a crucial factor, particularly when these molecules are used as recombinant drugs against tumors.
Paola, Cappello, Francesco, Novelli, Guido, Forni, Mirella, Giovarelli   +3 more
openaire   +2 more sources

Targeting TRAIL death receptors

Current Opinion in Pharmacology, 2008
The natural occurring tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis following binding to the two TRAIL death receptors (DRs). Its recombinant form and monoclonal antibodies against the TRAIL DRs induce cell death in a wide variety of tumor cell lines and xenografts without causing toxicity to normal cells and are ...
C N A M, Oldenhuis, J H, Stegehuis, A M E, Walenkamp, S, de Jong, E G E, de Vries   +4 more
openaire   +2 more sources

Death Receptor 5 and Neuroproliferation

Cellular and Molecular Neurobiology, 2011
Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand is a member of the tumor necrosis factor superfamily of cytokines that induces apoptosis upon binding to its death domain-containing transmembrane receptors, death receptors 4 and 5 (DR4, DR5).
Yanli, Niu, Yongqiang, Li, Jianfeng, Zang, Hongen, Huang, Jiexin, Deng, Zhanjun, Cui, Dongming, Yu, Jinbo, Deng   +7 more
openaire   +2 more sources

Death Receptor Signaling and Autoimmunity

Immunologic Research, 2003
In recent years, it has become clear that self-nonself discrimination by the immune system is driven not so much by the specificities of the antigen receptors themselves, but by ligand-receptor systems that sense the presence of foreign pathogens (toll-like receptors) and those that regulate the balance between cellular proliferation and programmed ...
Richard M, Siegel, Jagan, Muppidi, Margaret, Roberts, Melissa, Porter, Zhengqi, Wu   +4 more
openaire   +2 more sources

Death receptor 3 mediates necroptotic cell death

Cellular and Molecular Life Sciences, 2016
Death receptor 3 (DR3) was initially identified as a T cell co-stimulatory and pro-inflammatory molecule, but further studies revealed a more complex role of DR3 and its ligand TL1A. Although being a death receptor, DR3 gained to date predominantly attention as a contributor to inflammation-driven diseases.
Sebastian Bittner, Gertrud Knoll, Martin Ehrenschwender   +2 more
openaire   +2 more sources

Death receptor‐induced cell death in prostate cancer

Journal of Cellular Biochemistry, 2003
AbstractProstate cancer mortality results from metastasis and is often coupled with progression from androgen‐dependent to androgen‐independent growth. Unfortunately, no effective treatment for metastatic prostate cancer increasing patient survival is available. The absence of effective therapies reflects in part a lack of knowledge about the molecular
Natalya V, Guseva, Agshin F, Taghiyev, Oskar W, Rokhlin, Michael B, Cohen   +3 more
openaire   +2 more sources

Structural Studies of Death Receptors

2014
This chapter describes reports of the structural characterization of death ligands and death receptors (DRs) from the tumor necrosis factor (TNF) and TNF receptor families. The review discusses the interactions of these proteins with agonist ligands, inhibitors, and downstream signaling molecules.
openaire   +2 more sources